An observational study in Vascular Disease, Peripheral and Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer), sponsored by MIMOSA Diagnostics Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-11.
Sponsored by MIMOSA Diagnostics Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies in Peripheral Vascular Diseases with a site in United States — 18 open to participants now, 23 under way, 2 of them phase 3. Peripheral Vascular Diseases · United States.
Among the 187 studies in Peripheral Vascular Diseases with a site in United States, this one is the 20th largest by planned enrollment of the 26 observational ones that give a count, is one of 3 that started in 2025, is one of 26 observational ones, reaches primary completion later than 3 of the 22 other live ones, and was the 183rd registered.
443 studies on the registry are indexed under Peripheral Vascular Diseases; 44 are open to participants now.
Browse Peripheral Vascular Diseases studies →18 of the 187 studies in Peripheral Vascular Diseases with a site in United States are open now. Recruiting first, the newest first:
Cook Research Incorporated · Sites in United States
Ages 18+
Corewell Health West · Sites in United States
Ages 45+
Northwestern University · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 50–75 · Healthy volunteers
Versono Medical Ltd · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 32 Peripheral Vascular Diseases studies recruiting now, 19 (59%) set no upper age limit and 4 (13%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 36 · Phase 3 25 · Phase 4 11
First in 1994; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 217 across 86 observational studies indexed under Peripheral Vascular Diseases.
Median enrollment 82 across the 158 interventional studies, 200 across the 26 observational. Of the 147 that completed or were terminated, 57 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
92 of 187 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with MIMOSA Diagnostics Inc. as lead sponsor.
MIMOSA Diagnostics Inc. has 1 study filed under Peripheral Vascular Diseases — fewer than ten, so there is no comparison to draw.
10 of the studies in Peripheral Vascular Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07639853Medtronic EndovascularCase-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils | 2026-11 |
| NCT06492733Versono Medical LtdFastWire REvascularisation of Extremities, (For LOWer Limbs) - FREEFLOW | 2026-11 |
| NCT04922762Virginia Commonwealth UniversityExamining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 2 | 2026-12 |
| NCT06319339University of NebraskaImpact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease | 2026-12 |
| NCT06300450Brigham and Women's HospitalRandomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy | 2026-12-28 |
Add all 10 to your calendar (.ics) → With an account.
Among the 187 studies in Peripheral Vascular Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn if the measures of tissue oxygenation from the MIMOSA Pro imaging device correlate to standard vascular assessment tools in patients who receiving a lower extremity vascular assessment.
The main questions it aims to answer are:
Participants will be asked to follow standard of care, and also allow for their legs to imaged by the MIMOSA Pro.
Observational non-interventional study to assess the use of multispectral near-infrared (MS-NIR) imaging as an adjunct tool in the wound center. No clinical decisions will be made based on information obtained through the use of the MIMOSA device. Objectives are to correlate tissue oxygen saturation (StO2) by MS-NIR to measures by standard vascular diagnostic tools, including ankle-brachial index (ABI), toe-brachial index (TBI), transcutaneous oximetry, Doppler waveforms. Also to assess the ability of MS-NIR to support the classification and grading severity of patients' peripheral artery disease (PAD), venous disease and wound healing and to evaluate the clinical workflow utility of MS-NIR as an adjunct tool in the wound center. The study will recruit patients 18 years old and older, are undergoing an ankle-brachial index exam and recently had/will have further vascular assessment, as per standard of care (inc. transcutaneous oxygen pressure, Doppler waveforms). Participants will be asked to allow for imaging of their lower extremities with the MIMOSA Pro. Investigator will assess participants on their disease and wound status. They will also perform vascular assessments mentioned above as per standard of care. Participants will be followed for 2 months as per regularly scheduled visits. The standard vascular assessment results and disease/wound status will then be correlated with the measures from the MIMOSA Pro.
outpatient wound center
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Correlation coefficient between MIMOSA measures to standard vascular assessment modalities
Time frame: From baseline to the end of study at 2 months
Correlation coefficient between MIMOSA measures to disease and/or wound status
Time frame: From baseline to the end of study at 2 months
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Dec 2025, 7 months after the start.
Of 25 observational studies under Peripheral Vascular Diseases, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 95. This study's planned 7 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peripheral Vascular Diseases →